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Transcutaneous rather than plasma bilirubin "measurement" is certainly the most appropriate way to avoid unnecessary blood sampling, since jaundice is usually the most frequent finding among newborn infants. Our study, which included 210 full-term Caucasian newborn infants with no other findings but jaundice, showed a good correlation between transcutaneous bilirubin "measurement" and serum bilirubin levels (r = 0.894), with a negative predictive value of 98%, thus indicating that this method is an excellent way to avoid plasma bilirubin measurement.
However, even though limitations such as preterm birth, skin color, and previous exposure of newborn infants to phototherapy or exchange transfusion did not render the method inappropriate, they cast some doubt on its cost-benefit ratio.
Studies involving Bilicheck ® have shown great improvement when the device is used without any influence from gestational age, skin color, etc, allowing for its widespread use among jaundiced newborn infants. 3, 4 Nevertheless, when spectrophotometric principles are used, the correlation produced by each device varies, thereby exposing some limitations.
If we take into account the advantage of not having to perform venipuncture in newborn infants, a procedure that may require further punctures and result in infection and pain, the use of devices that avoid that is of paramount importance.
Therefore, the use of Bilicheck ® or of other similar devices is time-saving and prevents any complications that may arise from venipuncture.
Given the cost of Bilicheck ® , which is around US$ 10,500
(based on public bids, 2006), and the cost of plasma bilirubin measurement, which is around US$ 3, the nursery should perform at least around 9.7 assessments of hyperbilirubinemia a day (around 292 a month or 3,500 measurements a year).
So, the advantages of purchasing this device must be carefully weighed, since the calculations used in the study were roughly made, without assessing any other related parameters, such as possible maintenance and depreciation costs as well as indirect costs.
In our setting, expenses on other essential materials in extremely busy nurseries may render the use of such devices unfeasible.
Twenty-five years after the publication of our research study into this topic, we are still in doubt about the actual need of devices just like Bilicheck ® . This is not at all associated with its benefits, but with its costs instead.
The American Academy of Pediatrics has recommended that every newborn infant be assessed as to bilirubin levels before hospital discharge and that based on these levels they be referred for reassessment on the first days after discharge. 3 We believe Brazilian pediatric associations will soon adopt this procedure as well. This will certainly lead to a remarkable increase in laboratory bilirubin measurements and therefore the use of transcutaneous devices may be more economically feasible. We do hope that in the near future the price of these devices will go further down and that more financial resources will be allocated to neonatal care.
